Catalyst Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$732K Sell
610
-1,865
-75% -$1.91M 0.01% 155
2026
Q1
$2.28M Buy
+2,475
New +$2.51M 0.04% 102
2020
Q4
Sell
-39,800
Closed -$5.89M 358
2020
Q3
$5.89M Sell
39,800
-2,300
-5% -$356K 0.33% 49
2020
Q2
$6.91M Sell
42,100
-3,900
-8% -$599K 0.36% 42
2020
Q1
$6.38M Buy
+46,000
New +$6.32M 0.32% 44
2019
Q2
Sell
-379
Closed -$49K 449
2019
Q1
$49K Buy
379
+40
+12% +$4.86K ﹤0.01% 233
2018
Q4
$39K Buy
+339
New +$37.9K ﹤0.01% 266
2017
Q2
Sell
-210
Closed -$18K 533
2017
Q1
$18K Buy
+210
New +$16.8K ﹤0.01% 382
2016
Q4
Sell
-1,300
Closed -$104K 470
2016
Q3
$104K Buy
+1,300
New +$104K 0.01% 274
2014
Q3
Sell
-139,290
Closed -$8.66M 456
2014
Q2
$8.66M Buy
139,290
+31,254
+29% +$1.86M 1.41% 3
2014
Q1
$6.36M Buy
108,036
+60,865
+129% +$3.4M 1.44% 2
2013
Q4
$2.41M Buy
47,171
+25,764
+120% +$1.29M 0.78% 58
2013
Q3
$1.08M Buy
21,407
+10,067
+89% +$527K 0.59% 58
2013
Q2
$557K Buy
+11,340
New +$617K 0.43% 89

Other funds holding LLY

Catalyst Capital Advisors's LLY Position: Q2 2026 in Review

Catalyst Capital Advisors reduced its Eli Lilly (LLY) stake by 75% in Q2 2026, selling an estimated $1.91M and leaving 610 shares worth $732K. The position accounts for 0.01% of the portfolio, ranked #155.

Catalyst Capital Advisors first reported a position in LLY in Q2 2013 and has held it in 14 quarters since. The position peaked at $8.66M in Q2 2014. 1,857 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Catalyst Capital Advisors held 610 shares of Eli Lilly worth $732K as of Q2 2026.
  • Catalyst Capital Advisors sold 1,865 Eli Lilly shares in Q2 2026, an estimated $1.91M.
  • Eli Lilly made up 0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #155 holding.
  • Catalyst Capital Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 14 quarters since.
  • Catalyst Capital Advisors's Eli Lilly position peaked at $8.66M in Q2 2014.
  • 1,857 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.